The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Dose-escalation results from Phase Ib/IIa trial of AZD4573 + acalabrutinib in R/R DLBCL
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses dose-escalation results from a Phase Ib/IIa trial investigating acalabrutinib combined with the CDK9 inhibitor, AZD4573, in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL; NCT04630756). This patient cohort included patients who had previously been treated with CAR-T therapy. The study reported high response rates in this heavily pretreated population, with a manageable safety profile. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Hutchinson MediPharma: Consultancy; ADC Therapeutics: Consultancy, Research Funding; TG Therapeutics: Consultancy; Kite Gilead: Consultancy; Astrazeneca Acerta: Research Funding; ALX Oncology: Research Funding; Sobi: Research Funding; Roche Genentech: Consultancy.
